A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1–derived lentiviral vectors

Overview of attention for article published in Nature Protocols, May 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

policy: 1 policy source

patent: 11 patents

Readers on

mendeley: 141 Mendeley

So far, Altmetric has seen 11 patents that reference this research output.

GENE PERTURBATION IN HUMAN MONOCYTE-DERIVED DENDRITIC CELLS

Application WO-2026062044-A1

World Intellectual Property Organisation (WIPO)

26 Mar 2026

GENE PERTURBATION IN HUMAN MONOCYTE-DERIVED MACROPHAGES

Application WO-2026062037-A1

World Intellectual Property Organisation (WIPO)

26 Mar 2026

USE OF INHIBITOR OF GASDERMIND FOR TREATMENT OF RAC2 MONOGENIC DISORDERS

Application WO-2026012976-A1

World Intellectual Property Organisation (WIPO)

15 Jan 2026

NLRP3 INHIBITORS, PAK1/2 INHIBITORS AND/OR CASPASE 1 INHIBITORS FOR USE IN THE TREATMENT…

Application WO-2024261302-A1

World Intellectual Property Organisation (WIPO)

26 Dec 2024

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 7 additional patents.